查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2058142

嗜伊紅性食道炎（EoE）：新型療法、未滿足的需求和目標產品展望報告，2026 年

Eosinophilic Esophagitis (EoE) - Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026
出版日期: | 出版商: Thelansis Knowledge Partners | 英文 53 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

市場概覽

  • 美國廢氣排放處理（EoE）市場預計將從 2025 年的 2.71 億美元成長到 2035 年的 3.7 億美元，預測期內複合年成長率為 3.2%-3.5%。
  • 短期成長（2025-2030 年）相對強勁，這主要得益於生物製藥的普及和診斷率的提高。
  • PPI 佔市場主導地位（佔 36-40% 的佔有率），並且由於其成本效益和可及性，仍然是首選治療方法。
  • 局部皮質類固醇（Fluticasone、Budesonide）合計佔市場佔有率的 25-30%。
  • 生物製藥（Dupixent/Dupilumab）是一個高成長領域，預計市場佔有率將從 2025 年的 4% 穩步成長到 2035 年的 4.6% 以上。
  • AK002（relenterimab）、tezeperumab 和 APT-1011 等新興治療方法預計將促進收入成長，到 2035 年總合將超過 7,000 萬美元。
  • 雖然藥物治療是主要方法，但飲食療法和支持性護理雖然不太普遍，但在臨床上仍佔有重要地位。

嗜伊紅性食道炎(EoE) 的新治療方法及對 TPP 的深入了解

Thelansis 發布的「嗜伊紅性食道炎(EoE)：新型療法、未滿足的需求和 TPP 洞察報告，2026」全面分析了該適應症的關鍵新興治療方法和主要藥物發現機會，包括新興的競爭格局、未滿足的需求、目標產品概況 (TPP)、試驗設計和關鍵意見領袖 (KOL) 的見解。

嗜伊紅性食道炎（EoE）概述

嗜伊紅性食道炎（EoE），常被稱為「食道氣喘」，是一種慢性免疫介導的2型發炎性疾病，其特徵是食道黏膜中大量嗜酸性粒細胞浸潤，導致進行性結構重塑和功能障礙。此病由Th2介導的免疫通路觸發，並與氣喘、過敏性鼻炎、濕疹和食物過敏等特異性疾病密切相關。內視鏡切片檢查可確診，顯示食道內有局限性嗜酸性粒細胞浸潤，且每個高倍視野（epox/hpf）中嗜酸性粒細胞超過15個。

嗜酸性粒細胞性食道炎的臨床症狀隨年齡而異。在兒童患者中，嘔吐、腹痛、逆流和進食困難較為常見；而在青少年和成人患者中，吞嚥困難、食物滯留和胸部不適（通常與纖維性狹窄的改變有關）是典型症狀。

這種疾病呈進行性發展，如果不加以適當治療，就會從發炎期轉變為纖維性狹窄型。

目前的治療策略包括質子幫浦阻斷劑（PPI）、局部皮質類固醇（如Budesonide和Fluticasone）、飲食療法，以及用於中度至重度病例的生物製藥（如度普利尤單抗）。對於難治性或重症患者，生物製藥如度普利尤單抗（一種IL-4/IL-13抑制劑）透過標靶潛在的免疫通路，在治療方面取得了顯著進展。

儘管治療方法取得了進展，但嗜酸性粒細胞性食道炎仍然是一種慢性複發性疾病，需要長期管理，目前還沒有根治性或緩解疾病的治療方法。

主要亮點

  • 據估計，2025年美國新患者數為27,008例，預計到2035年將增加至28,897例。這反映了在診斷技術進步和人們對該疾病認知不斷提高的推動下，病例數的穩定成長。
  • 受影響的人數明顯增多，預計將從 2025 年的 53,671 人增加到 2035 年的 57,423 人，這凸顯了該疾病的慢性性質以及患者患病的長期過程。
  • 預計到 2025 年確診患者人數為 46,693 人，到 2035 年將增至 49,958 人。這表明診斷率正在逐步提高，但病例數和確診人數之間仍然存在差距。
  • 這種疾病在男性中更為常見，預計到 2035 年，男性患者人數將超過女性患者人數（比例為 2.2 比 1）。
  • EoE 影響範圍很廣，年齡範圍很廣，在青年和中年人（21-40 歲）中的發病率最高，但兒童病例也佔著重要的臨床地位。
  • 大多數病例為中度，其次為重度，最後為輕度。
  • 吞嚥困難是最常見的症狀，2025 年有 29,948 名患者受其影響，預計到 2035 年將增加到 32,042 名患者。其次是腹痛/消化不良和食道結構併發症。

基於對醫生和關鍵意見領袖（KOL）的調查得出的結論：

  • 透過對關鍵意見領袖 (KOL) 的訪談，我們獲得了更深入的見解，從而進一步豐富了研究成果。
  • 調查問卷將根據客戶的要求進行客製化。

交付成果格式：

  • PowerPoint簡報
  • MS Excel

主要問題

  • 詳細的競爭格局趨勢
  • 管道分析
  • 符合新興治療方法的患者
  • 大公司
  • 主要作用機制
  • 發布日期等的預測
  • 臨床試驗趨勢分析
  • 目標患者群
  • 試驗終點
  • 測試設計
  • 受試者招募標準等。
  • 未滿足的需求和機遇
  • 目前主要治療方法的有效性
  • 未滿足需求的關鍵領域
  • 估算主要未滿足需求的市場規模
  • 目標產品概況
  • 屬性和級別
  • 醫生開立的處方
  • 預期患者佔有率
  • 關鍵KOL洞察對領先新興治療方法的見解
  • 意識
  • 預期用途/處理線
  • 對主要未滿足需求的滿意度
  • KOL評論

目標國家

  • G8
    • 美國
    • EU5
      • 法國
      • 德國
      • 義大利
      • 西班牙
      • 英國
    • 日本
    • 中國

大公司

  • Sanofi
  • AstraZeneca
  • NexEos Diagnostics, Inc.
  • Celldex Therapeutics
  • Eupraxia Pharmaceuticals Inc.
  • Revolo Biotherapeutics
  • Celgene
  • Ellodi Pharmaceuticals, LP
  • Phathom Pharmaceuticals, Inc.
  • AQILION AB
  • Uniquity One（UNI）
  • Regeneron Pharmaceuticals

目錄

第1章：主要調查結果及分析師說明

  • 主要趨勢：市場概況、SWOT分析、商業性利益與風險等。

第2章 競爭情勢

  • 目前的治療方法
  • 重點
  • 診斷和治療過程/演算法
  • 主要治療方法概述及KOL洞察
  • 新興治療方法
  • 重點
  • 診斷和治療過程/演算法
  • 領先的新興治療方法—概述和KOL洞察

第3章 產品屬性分析

  • 重點
  • 科學屬性
  • 商業性屬性
  • 產品定位

第4章：一級市場調查

  • 目前治療狀態
  • 主要治療方法與目標患者族群的比較
  • 主要特點和優勢
  • 未來治療環境
  • 當前挑戰
  • 未滿足的需求
  • 新興治療方法
  • 主要治療方法和目標患者群
  • 主要特點和優勢
  • 未來治療前景
  • 未滿足的需求和關鍵意見領袖的期望

第5章：未滿足的需求和TPP分析

  • 新興治療方法的主要未滿足需求和未來成就
  • TPP分析與KOL預期

第6章 監理與報銷環境

第7章附錄

簡介目錄

Eosinophilic Esophagitis (EoE) Emerging Therapy and TPP Insights

Thelansis's "Eosinophilic Esophagitis (EoE) Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026" provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Eosinophilic Esophagitis (EoE) Overview

Eosinophilic Esophagitis (EoE), often described as the "asthma of the esophagus," is a chronic, immune-mediated Type 2 inflammatory disease characterized by dense eosinophilic infiltration of the esophageal mucosa, leading to progressive structural remodeling and functional impairment. The disease is driven by Th2-mediated immune pathways and is strongly associated with atopic conditions such as asthma, allergic rhinitis, eczema, and food allergies. Diagnosis is confirmed via endoscopic biopsy demonstrating >=15 eosinophils per high-power field (eos/hpf), localized to the esophagus.

EoE presents with age-dependent clinical manifestations: Pediatric patients commonly experience vomiting, abdominal pain, regurgitation, and feeding difficulties, while adolescents and adults typically present with dysphagia, food impaction, and chest discomfort, often linked to fibrostenotic changes.

The disease follows a progressive course, transitioning from inflammatory to fibrostenotic phenotypes if not adequately managed.

Current treatment strategies include proton pump inhibitors (PPIs), topical corticosteroids (e.g., budesonide, fluticasone), dietary management, and biologics (e.g., dupilumab) in moderate-to-severe cases. For patients with refractory or severe disease, biologic therapies such as dupilumab (IL-4/IL-13 inhibitor) have significantly advanced treatment by targeting the underlying immunological pathways.

Despite therapeutic advancements, EoE remains a chronic, relapsing condition requiring long-term management, with no curative or disease-modifying therapies currently available.

Key Highlights

  • The incident EoE population in the United States is estimated at 27,008 cases in 2025, increasing to 28,897 by 2035, reflecting a steady rise driven by improved diagnosis and awareness.
  • The prevalent population is significantly larger, projected to grow from 53,671 in 2025 to 57,423 by 2035, highlighting the chronic nature of the disease and long patient duration.
  • The diagnosed population is estimated at 46,693 in 2025, increasing to 49,958 by 2035, indicating gradual improvement in diagnosis rates but still suggesting a gap between prevalence and diagnosis.
  • A male predominance is observed, with male cases vs female cases increasing by 2035 (2.2:1 ratio).
  • EoE affects a broad age range, with the highest burden observed in young and middle-aged adults (21-40 years), though pediatric cases remain clinically significant.
  • Disease severity is largely skewed toward moderate cases, followed by severe and mild segments.
  • Dysphagia is the most common symptom, affecting 29,948 patients in 2025, increasing to 32,042 by 2035, followed by abdominal pain/dyspepsia and esophageal structural complications.

Market Overview

  • The EoE treatment market in the US is projected to grow from $271 million in 2025 to $370 million by 2035, reflecting a CAGR of 3.2-3.5% over the forecast period.
  • Short-term growth (2025-2030) is relatively stronger, driven by increased adoption of biologics and improved diagnosis rates.
  • PPIs dominate the market (36-40% share), remaining first-line therapy due to cost-effectiveness and accessibility.
  • Topical corticosteroids (fluticasone, budesonide) account for 25-30% combined share.
  • Biologics (Dupixent/dupilumab) represent a high-growth segment, with share increasing steadily from 4% in 2025 to 4.6%+ by 2035.
  • Emerging therapies such as AK002 (lirentelimab), tezepelumab, and APT-1011 contribute incremental revenue, collectively reaching $70M+ by 2035
  • Pharmacological therapies dominate, while dietary and supportive therapies contribute smaller shares but remain clinically relevant.

Insights driven by surveys with physician / key opinion leaders:

  • Survey findings are corroborated and enriched by insights from interviews with leading KOLs
  • Survey is customized based on client requirements

Deliverables format:

  • PowerPoint presentation
  • MS Excel

Key business questions answered:

  • Detailed emerging competitive landscape
  • Pipeline analysis
  • Target patients for emerging therapies
  • Key companies
  • Key mechanism of actions
  • Launch date estimates, etc.
  • Clinical trial landscape analysis
  • Target patient segments
  • Trial endpoints
  • Trial design
  • Recruitment criteria, etc.
  • Unmet Needs and Opportunities
  • Performance of key current therapies
  • Top areas of unmet needs
  • Opportunity sizing for key unmet needs
  • Target Product Profiles
  • Attributes and levels
  • Physician likelihood of prescribing
  • Expected patient shares
  • KOL insights on key emerging therapies
  • Level of awareness
  • Expected use / line of therapy
  • Extent to fulfil key unmet needs
  • KOL quotes

Countries Covered

  • G8
    • United States
    • EU5
      • France
      • Germany
      • Italy
      • Spain
      • U.K.
    • Japan
    • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

  • Sanofi
  • AstraZeneca
  • NexEos Diagnostics, Inc.
  • Celldex Therapeutics
  • Eupraxia Pharmaceuticals Inc.
  • Revolo Biotherapeutics
  • Celgene
  • Ellodi Pharmaceuticals, LP
  • Phathom Pharmaceuticals, Inc.
  • AQILION AB
  • Uniquity One (UNI)
  • Regeneron Pharmaceuticals

Table of Contents

1. Key Findings and Analyst Commentary

  • Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc.

2. Competitive Landscape

  • Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies - profiles and KOL insights
  • Emerging therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key emerging therapies - profiles and KOL insights

3. Product Attribute Analysis

  • Key takeaways
  • Scientific attributes
  • Commercial attributes
  • Product positioning

4. Primary Market Research

  • Current treatment landscape
  • Key therapies vs. focused patient segment
  • Key attributes and benefits
  • Futures treatment landscape
  • Current challenges
  • Unmet needs
  • Emerging therapies
  • Key therapies vs. focused patient segment
  • Key attributes and benefits
  • Futures treatment landscape
  • Unmet needs and KOL expectations

5. Unmet Need and TPP Analysis

  • Top unmet needs and future attainment by emerging therapies
  • TPP analysis and KOL expectations

6. Regulatory and Reimbursement Environments (by country and payer insights)

7. Appendix (e.g., bibliography, methodology)